Yunho Biotechnology was established in January 2022, mainly engaged in the research and development of small nucleic acid drugs, focusing on AI driven RNAi innovative therapy development. At the same time, it has established an AI assisted full process small nucleic acid drug development platform, multi organ targeted delivery system, and chemical modification platform, which can achieve cost reduction and efficiency improvement in drug research and development. The core team has complementary strengths and obvious comparative advantages in their respective areas of expertise, making them a highly professional nucleic acid drug research and development management team in China.